Autoantibodies Directed Against the Ribosomal P Proteins are not only Directed Against a Common Epitope of the P0, P1 and P2 Proteins

Fabien, Nicole; Moreira, Annick; Lavergne, Jean‐Pierre; Desbos, Agnès; Surgey, Patricia; Olivera, Cécile Alves de; Gonzalo, Philippe; Venot, Annick; Bienvenu, Jacques; Perrier, H.; Reboud, Jean‐Paul; Monier, J. C.

doi:10.1006/jaut.1999.0291

Cited by 26 publications

(24 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in keeping with the N-terminal epitopes reported by Fabien and colleagues, who argued against the use of the C22 peptide for the detection of antiribosomal antibodies (10). Based on this background, an anti-Rib-P screening ELISA using the three recombinant proteins in the molar ratio of the native heterocomplex, P0(P1/ P2) 2 , was developed for this study.…”

supporting

confidence: 81%

International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins

Mähler

Kessenbrock

Szmyrka

et al. 2006

Clin Vaccine Immunol

View full text Add to dashboard Cite

Autoantibodies to the ribosomal phosphoproteins (Rib-P) are a serological feature of patients with systemic lupus erythematosus (SLE). The reported prevalence of anti-Rib-P antibodies in SLE ranges from 10 to 40%, being higher in Asian patients. The variation in the observed frequency may be related to a number of factors but is dependent in large part on the test system used to detect the autoantibodies. An association of anti-Rib-P with central nervous system involvement and neuropsychiatric manifestations of SLE has been controversial. In the present international multicenter study, we evaluated the clinical accuracy of a new sensitive Rib-Pspecific enzyme-linked immunosorbent assay based on recombinant Rib-P polypeptides. The results showed that 21.3% of 947 SLE patients, but only 0.7% of 1,113 control patients, had a positive test result (P < 0.0001). The sensitivity, specificity, positive and negative predictive values, and diagnostic efficiency were determined to be 21.3%, 99.3%, 95.6%, 62.2%, and 65.3%, respectively. When evaluated in the context of participating centers, the prevalence of anti-Rib-P antibodies was found in descending frequency, as follows: China (35%) > Poland (34%) > Japan (28%) > United States (26%) > Germany (Freiburg; 23.3%) > Denmark (20.5%) > Germany (Berlin; 19%) > Mexico (15.7%) > Israel (11.7%) > Brazil (10%) > Canada (8%). The substantial data from this study indicate that the prevalence of anti-Rib-P antibodies may not be restricted to the genetic background of the patients or to the detection system but may depend on regional practice differences and patient selection. We confirm previously reported associations of antiribosomal antibodies with clinical symptoms and serological findings. Remarkably, we found a lower occurrence of serositis in Rib-P-positive lupus patients.Autoantibodies to the ribosomal phosphoproteins (Rib-P) are a serological feature of patients with systemic lupus erythematosus (SLE) (4,8,9). The Rib-P autoantigen(s) consists of three protein components of the 60S ribosomal subunit, designated P0 (38 kDa), P1 (19 kDa), and P2 (17 kDa) (8, 12). A pentameric complex composed of one copy of P0 and two copies each of P1 and P2 interacts with the 28S rRNA molecule to form a GTPase domain, which is active during the elongation step of protein translation (8). The major immunoreactive epitope of this ribosomal autoantigen has been localized to the carboxy-terminal domain, which is highly conserved in all three proteins and contains two phosphorylated serine residues (e.g., Ser 102 and Ser 105 of human P2) (8,16,17). Several studies have shown that both the acidic and hydrophobic clusters, but not the phosphorylation of the P proteins, are critical for autoantibody binding (8,16,23). Furthermore, epitope mapping studies have shown that the major epitope domain is located within the last six C-terminal amino acids (GFGLFD) (8,16,23).The reported prevalence of anti-Rib-P antibodies in SLE ranges from 10 to 40%, being higher in Asian patients and at a relatively low...

show abstract

supporting

confidence: 81%

International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins

Mähler

Kessenbrock

Szmyrka

et al. 2006

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…More recently, there is growing evidence of an antibody recognition mediated by conformational determinants on P proteins [17]. Moreover, anti-P antibodies may recognize epitopes not shared by the three P proteins and some of them are also directed to the N-terminal sequence [18].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays

Ghirardello

Caponi

Franceschini

et al. 2002

Journal of Autoimmunity

View full text Add to dashboard Cite

“…I. Moosbrugger, Private Institute for Immunology and Molecular Genetics, Karlsruhe, Germany). The immunoblotting technique was previously described (7). Briefly, the antigen was loaded (20 g/lane) onto a 10% polyacrylamide gel containing 0.1% sodium dodecyl sulfate.…”

Section: Detection Of Aabs Against the Casrmentioning

confidence: 99%

Calcium-Sensing Receptor Autoantibodies Are Relevant Markers of Acquired Hypoparathyroidism

Mayer

Ploix

Orgiazzi

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

Self Cite

View full text Add to dashboard Cite

We investigated the presence of autoantibodies (aAbs) directed against the parathyroid gland in 17 patients with spontaneous isolated acquired hypoparathyroidism. Fourteen patients with acquired hypoparathyroidism (AH) associated with type I or II autoimmune polyendocrinopathy syndrome were also tested in comparison with a control group of 68 subjects without AH, including patients with other autoimmune diseases and healthy blood donors. aAbs against parathyroid tissue were screened using an indirect immunofluorescence technique on primate parathyroid tissue and human parathyroid adenoma. aAbs against the calcium-sensing receptor (CaSR) were analyzed using an immunoblotting assay with the recombinant extracellular domain of the human

show abstract

Autoantibodies Directed Against the Ribosomal P Proteins are not only Directed Against a Common Epitope of the P0, P1 and P2 Proteins

Cited by 26 publications

References 20 publications

International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins

International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins

Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays

Calcium-Sensing Receptor Autoantibodies Are Relevant Markers of Acquired Hypoparathyroidism

Contact Info

Product

Resources

About